Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04523857
Title ABemacicliB, HydroxYchloroquine, or the Combination to Target Minimal Residual Disease in Breast Cancer (ABBY)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

breast cancer

Therapies

Abemaciclib

Abemaciclib + Hydroxychloroquine

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.